COST-EFFECTIVENESS ANALYSIS OF LURASIDONE AND OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA

被引：0
|
作者：
Priyadarshini, M. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1380
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH40
引用
下载
收藏
页码：A188 / A189
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of current and optimal treatment for schizophrenia
    Andrews, G
    Sanderson, K
    Corry, J
    Issakidis, C
    Lapsley, H
    BRITISH JOURNAL OF PSYCHIATRY, 2003, 183 : 427 - 435
  • [32] COST-EFFECTIVENESS STUDIES IN THE TREATMENT OF SCHIZOPHRENIA - A REVIEW
    GOLDBERG, D
    SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 1991, 26 (03) : 139 - 142
  • [33] COST-EFFECTIVENESS OF ASENAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN CANADA
    Lachaine, J.
    Beauchemin, C.
    Mathurin, K.
    Gilbert, D.
    Beillat, M.
    Corson, H.
    VALUE IN HEALTH, 2012, 15 (04) : A88 - A88
  • [34] Cost-effectiveness of olanzapine as a first-line treatment: A comment
    Basu, Anirban
    VALUE IN HEALTH, 2006, 9 (05) : 357 - 357
  • [35] Cost-Effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States
    Svanum, Ascher H.
    Furiak, N. M.
    Klein, R. W.
    Smolen, L. J.
    Lawson, A. H.
    Conley, R. R.
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2009, 12 : S3 - S4
  • [36] Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
    Furiak N.M.
    Ascher-Svanum H.
    Klein R.W.
    Smolen L.J.
    Lawson A.H.
    Conley R.R.
    Culler S.D.
    Cost Effectiveness and Resource Allocation, 7 (1)
  • [37] COST-UTILITY ANALYSIS OF LURASIDONE FOR THE TREATMENT OF SCHIZOPHRENIA IN CHINA
    Cao, D.
    Liu, J.
    Liu, J.
    He, X.
    Wu, J.
    VALUE IN HEALTH, 2021, 24 : S133 - S133
  • [38] Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder
    Kasteng, F.
    Eriksson, J.
    Sennfalt, K.
    Lindgren, P.
    ACTA PSYCHIATRICA SCANDINAVICA, 2011, 124 (03) : 214 - 225
  • [39] Cost-effectiveness analysis of ziprasidone versus no treatment for schizophrenia relapse prevention
    Azanza, JR
    Bernardo, M
    Rubio-Terrés, C
    Díez, T
    Rejas, J
    VALUE IN HEALTH, 2005, 8 (06) : A204 - A204
  • [40] Schizophrenia treatment in the developing world:: an interregional and multinational cost-effectiveness analysis
    Chisholm, Dan
    Gureje, Oye
    Saldivia, Sandra
    Calderon, Marcelo Villalon
    Wickremasinghe, Rajitha
    Mendis, Nalaka
    Ayuso-Mateos, Jose-Luis
    Saxena, Shekhar
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2008, 86 (07) : 542 - 551
12345